双环醇片联合胸腺肽治疗慢性乙型肝炎疗效和安全性分析

Effectiveness and safety of bicyclol combined with thymosin in treatment of chronic viral hepatitis B

目的研究双环醇片联合胸腺肽治疗慢性乙型肝炎的疗效和安全性。方法随机选择135例慢性乙型肝炎患者分2组接受治疗,试验组,68例,每日口服双环醇片75mg,同时使用胸腺肽20mg,肌内注射,隔日一次,对照组,67例,仅给予每日口服双环醇片75mg,2组均连续用药24周。观察治疗前后血清氨基转移酶水平及血清病毒学标志方面的改变。结果2组血清氨基转移酶均得到明显下降,但差异无统计学意义。试验组HBeAg阴转率(35.3%)显著高于对照组(19.4%)P<0.05,HBeAg血清转换率(22.0%)虽高于对照组(14.9%),但差异无统计学意义,HBVDNA阴转率(36.7%)显著高于对照组(20.9%)P<0.05。2组均未出现明显不良反应。结论双环醇片和胸腺肽联合应用治疗慢性乙型肝炎可提高抗病毒疗效且安全。

Objective To analyze the efficacy and safety of bicyclol combined with thymosin in treatment of chronic viral hepatitis B （CHB）. Methods A total of 135 patients with CHB were randomized into experimental group and control group. The patients in the experimental group received bicyclol orally 75 mg daily and thymosin 20 mg intramuscular injection once every 2 days for 24 weeks and those in control group received bicyclol orally 75 mg daily alone for 24 weeks. The levels of serum aminotransferase（ ALT/AST）, HBV-DNA, HBeAg/antiHBe were observed. Results Compared with pre-treatment levels, the serum aminotransferase levels decreased significantly in both groups, but there were no statistically significant differences between them. HBeAg negative conversion rate was significantly higher in the experimental group than in the control group （35.3% vs. 19.4%, P 〈 0.05）. HBV DNA negative conversion rate was significantly higher in the experimental group than in the control group （36.7% vs. 20.9%, P 〈 0.05）. No obvious adverse events which were probably related to the drugs were observed in this study. Conclusion The combination of bicyclol with thymosin had better effect in treatment of chronic hepatitis B is compared with bicyvlol alone.